An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2016 Planned End Date changed from 1 Jan 2021 to 1 Jan 2020.
- 12 Dec 2016 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2020.